Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
04 janv. 2022 07h00 HE
|
Advicenne
Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region Advicenne will receive a transfer price and royalties for an amount markedly higher than 50%...
Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA
20 déc. 2021 07h00 HE
|
Advicenne
Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA ...
Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe
07 déc. 2021 07h00 HE
|
Advicenne
Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe First round of pricing negotiations completed in the United KingdomTwinPharma and ExCEEd Orphan to...
Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA
02 juil. 2021 01h00 HE
|
Advicenne
Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA ...
Advicenne provides an update on its activities following its Annual General Meeting
15 juin 2021 12h17 HE
|
Advicenne
Advicenne provides an update on its activities followingits Annual General Meeting Introducing Advicenne 2.0, the Company’s strategy to unlock valuePoised to partner Sibnayal in dRTA in Europe...
Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)
17 mai 2021 12h03 HE
|
Advicenne
Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA) FDA accepts amended protocol...
Advicenne reçoit un avis positif de la FDA sur la procédure d'approbation et l’Agence accepte le protocole modifié de l'étude de phase III pour son traitement de l'acidose tubulaire rénale distale (ATRd)
17 mai 2021 12h00 HE
|
Advicenne
Advicenne reçoit un avis positif de la FDA sur la procédure d'approbation et l’Agence accepte le protocole modifié de l'étude de phase III pour son traitement de l'acidose tubulaire rénale distale...